Newsletter | February 2024 Recap

Partnership with LegoChem Biosciences for ADC development and manufacturing

Samsung Biologics announced it has signed a partnership agreement with LegoChem Biosciences, a biotech company pioneering the research and development of antibody-drug conjugate (ADC) programs. Under the terms of the deal, the company will provide antibody development and drug substance manufacturing services as a part of LegoChem Biosciences’ ADC program designed to treat solid tumors. Read more

Awarded Leadership status by CDP for climate action efforts

Samsung Biologics received the Leadership status and A- rating from the Carbon Disclosure Project (CDP). The leadership status reflects the company's progress in sustainability management and collaborative efforts to decarbonize across the supply chain. The company will continue its environmental stewardship by implementing better services and practices along with our clients and suppliers to mitigate climate risks and build a healthier future. Read more

MEDIA FOCUS

Expansion into late drug discovery and early development

Selecting biologic compounds with optimal stability and developability is critical for successful drug development. In this article, Derrick Katayama, Lead Scientist in Formulation Development, explains how Samsung Biologics utilizes proprietary platforms, DEVELOPICK? and S-CHOsient?, to streamline processes and enhance efficiency. Read more

Integrated CMC Solutions in the Complex Biologics Space

Multiple complexities can arise during the path from clinic to commercialization for biologics.?In this article, Jimin Kim, senior CDO business strategist, discusses the evolving biologics landscape and highlights how an experienced CDMO with integrated CMC solutions can overcome challenges and offer expertise and solutions. Read more

WHITEPAPER

Optimizing sialic acid clone screening through a high throughput lectin assay

As glycosylation can significantly impact protein stability, folding, and solubility during early development, establishing a robust glycosylation control strategy is critical to ensure success.?In this whitepaper, we discuss how the implementation of high-throughput lectin assay can lower immunogenicity and optimize pharmacokinetics and pharmacodynamics for recombinant therapeutics.?Read more

UPCOMING EVENTS